IDEAYA Biosciences Inc. Stock News

IDEAYA Biosciences, Inc.'s platform is synthetic lethality targeting cancer. The company has produced solid proof of concept data from multiple programs.

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.28% and 48.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the s

SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de

SOUTH SAN FRANCISCO, Calif. , Nov. 29, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and de

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 106.15% and 271.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th

SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and dev

Shares have posted a 40% loss over the past 12 months. I have added confidence in prospects for darovasertib in uveal melanoma given monotherapy activity as well as high ORR and PFS relative to compet

Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0% and 26.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The biotech bear market has been particularly hard on Precision Oncology companies - particularly those that came to market on the back of lucrative IPOs. Ideaya IPO'd in 2019, raising a modest $55m,

SOUTH SAN FRANCISCO, Calif. , June 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and dev

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc

IDEAYA Biosciences, Inc. (IDYA) CEO Yujiro Hata on Q4 2021 Results and Interim Clinical Data Update - Earnings Call Transcript

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -51.61% and 70.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the